ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.
Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.